Articles related to DRUG SAFETY & INTERACTIONS

The FDA classified the nationwide recall of more than 2.5 million bottles of Lupin’s prednisolone acetate ophthalmic suspension as a Class II recall after reports of a foreign substance in affected products.

Statin exposure in LPS-primed mouse muscle cells activated NLRP3 inflammasome signaling and reduced protein prenylation, producing atrophy markers and grip strength loss in a preclinical model of statin myopathy.

The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.

Breckenridge Pharmaceutical initiated a voluntary Class II recall of duloxetine delayed-release capsules 60 mg (Lot 241069C, expiration May 31, 2027) on April 21, 2026, following detection of elevated N-nitroso-duloxetine impurity levels attributed to CGMP deviations at the Barcelona manufacturing site, affecting 165,761 bottles distributed nationwide.

Sedative-hypnotic drug effects vary with meal timing, metabolism, and drug half-life in patients with insomnia. These pharmacologic factors influence sleep onset and maintenance, particularly in patients with psychiatric comorbidities requiring concurrent medications.